This Article Full Text Full Text (PDF) All Versions of this Article: 109/15/1819    most recent 01.CIR.0000126837.88743.DDv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schäfer, A. Articles by Channon, K. M. Search for Related Content PubMed PubMed Citation Articles by Schäfer, A. Articles by Channon, K. M. Related Collections Platelets Endothelium/vascular type/nitric oxide

(Circulation. 2004;109:1819-1822.)
© 2004 American Heart Association, Inc.

Brief Rapid Communications

Rapid Regulation of Platelet Activation In Vivo by Nitric Oxide

Andreas Schäfer, MD^*; Frank Wiesmann, MD^*; Stefan Neubauer, MD, FRCP; Martin Eigenthaler, MD; Johann Bauersachs, MD; Keith M. Channon, MD, FRCP

From the Department of Cardiovascular Medicine, University of Oxford, UK (A.S., F.W., S.N., K.M.C.), and Medizinische Klinik (A.S., F.W., J.B.) and Institut für Klinische Biochemie und Pathobiochemie (M.E.), Julius-Maximilians-Universität Würzburg, Würzburg, Germany.

Correspondence to Professor Dr Keith M. Channon, Department of Cardiovascular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, UK. E-mail keith.channon{at}cardiov.ox.ac.uk

Received July 28, 2003; revision received January 22, 2004; accepted March 1, 2004.

Background— Platelet activation is a feature of many cardiovascular diseases characterized by endothelial dysfunction. The mechanistic relationship between impaired systemic nitric oxide (NO) bioavailability and platelet activation in vivo remains unclear. We investigated whether acute inhibition of NO production in humans modulates platelet activation in vivo and whether exogenous NO would counteract such an effect.

Methods and Results— Intravenous injection of the NO synthase inhibitor N^G-monomethyl-L-arginine in healthy volunteers resulted in NO synthase inhibition as detected by increased blood pressure and by significantly reduced phosphorylation of platelet vasodilator-stimulated phosphoprotein, an indicator of NO signaling. NO synthase inhibition increased platelet activation as determined by enhanced platelet binding of fibrinogen and surface expression of P-selectin, glycoprotein 53, and CD40 ligand, demonstrating tonic inhibition of platelet activation by NO production in vivo. Sublingual administration of the NO donor glyceryl trinitrate normalized platelet VASP phosphorylation and restored markers of platelet activation to baseline levels.

Conclusions— Acute inhibition of endogenous NO production in humans causes rapid platelet activation in vivo, which is reversed by exogenous NO, demonstrating that platelet function in vivo is rapidly regulated by NO bioavailability.

Key Words: glycoproteins • nitric oxide • P-selectin • phosphoproteins • platelets

This article has been cited by other articles:

				H. Imrie, A. Abbas, H. Viswambharan, A. Rajwani, R. M. Cubbon, M. Gage, M. Kahn, V. A. Ezzat, E. R. Duncan, P. J. Grant, et al. Vascular Insulin-Like Growth Factor-I Resistance and Diet-Induced Obesity Endocrinology, October 1, 2009; 150(10): 4575 - 4582. [Abstract] [Full Text] [PDF]

				C. Antoniades, C. Bakogiannis, D. Tousoulis, A. S. Antonopoulos, and C. Stefanadis The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J. Am. Coll. Cardiol., August 18, 2009; 54(8): 669 - 677. [Abstract] [Full Text] [PDF]

				A. Schafer, D. Fraccarollo, J. Widder, M. Eigenthaler, G. Ertl, and J. Bauersachs Inhibition of platelet activation in rats with severe congestive heart failure by a novel endothelial nitric oxide synthase transcription enhancer Eur J Heart Fail, April 1, 2009; 11(4): 336 - 341. [Abstract] [Full Text] [PDF]

				M. T. Kearney, E. R. Duncan, M. Kahn, and S. B. Wheatcroft Insulin resistance and endothelial cell dysfunction: studies in mammalian models Exp Physiol, January 1, 2008; 93(1): 158 - 163. [Abstract] [Full Text] [PDF]

				P. Hillmen, P. Muus, U. Duhrsen, A. M. Risitano, J. Schubert, L. Luzzatto, H. Schrezenmeier, J. Szer, R. A. Brodsky, A. Hill, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria Blood, December 1, 2007; 110(12): 4123 - 4128. [Abstract] [Full Text] [PDF]

				R. M Cubbon, A. Rajwani, and S. B Wheatcroft The impact of insulin resistance on endothelial function, progenitor cells and repair Diabetes and Vascular Disease Research, June 1, 2007; 4(2): 103 - 111. [Abstract] [PDF]

				T. M.C. Brunini, A. C. Mendes-Ribeiro, J. C. Ellory, and G. E. Mann Platelet nitric oxide synthesis in uremia and malnutrition: A role for L-arginine supplementation in vascular protection? Cardiovasc Res, January 15, 2007; 73(2): 359 - 367. [Abstract] [Full Text] [PDF]

				A. Schafer, U. Flierl, A. Kobsar, M. Eigenthaler, G. Ertl, and J. Bauersachs Soluble Guanylyl Cyclase Activation With HMR1766 Attenuates Platelet Activation in Diabetic Rats Arterioscler Thromb Vasc Biol, December 1, 2006; 26(12): 2813 - 2818. [Abstract] [Full Text] [PDF]

				I. Chung and G. Y.H. Lip Platelets and heart failure Eur. Heart J., November 2, 2006; 27(22): 2623 - 2631. [Abstract] [Full Text] [PDF]

				C. Antoniades, D. Tousoulis, C. Vasiliadou, E. Stefanadi, K. Marinou, and C. Stefanadis Genetic Polymorphisms of Platelet Glycoprotein Ia and the Risk for Premature Myocardial Infarction: Effects on the Release of sCD40L During the Acute Phase of Premature Myocardial Infarction J. Am. Coll. Cardiol., May 16, 2006; 47(10): 1959 - 1966. [Abstract] [Full Text] [PDF]

				I. L Williams, P. J Chowienczyk, S. B Wheatcroft, A. G Patel, R. A Sherwood, A. M Shah, and M. T Kearney Divergent effects of angiotensin-converting enzyme inhibition on blood pressure and endothelial function in obese humans Diabetes and Vascular Disease Research, May 1, 2006; 3(1): 34 - 38. [Abstract] [PDF]

				S. R. Willoughby, S. Stewart, A. S. Holmes, Y. Y. Chirkov, and J. D. Horowitz Platelet Nitric Oxide Responsiveness: A Novel Prognostic Marker in Acute Coronary Syndromes Arterioscler Thromb Vasc Biol, December 1, 2005; 25(12): 2661 - 2666. [Abstract] [Full Text] [PDF]

				P. C. Williams, M. J. Coffey, B. Coles, S. Sanchez, J. D. Morrow, J. R. Cockcroft, M. J. Lewis, and V. B. O'Donnell In vivo aspirin supplementation inhibits nitric oxide consumption by human platelets Blood, October 15, 2005; 106(8): 2737 - 2743. [Abstract] [Full Text] [PDF]

				A. Hill, P. Hillmen, S. J. Richards, D. Elebute, J. C. Marsh, J. Chan, C. F. Mojcik, and R. P. Rother Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria Blood, October 1, 2005; 106(7): 2559 - 2565. [Abstract] [Full Text] [PDF]

				A. Schafer, D. Fraccarollo, M. Eigenthaler, P. Tas, A. Firnschild, S. Frantz, G. Ertl, and J. Bauersachs Rosuvastatin Reduces Platelet Activation in Heart Failure: Role of NO Bioavailability Arterioscler Thromb Vasc Biol, May 1, 2005; 25(5): 1071 - 1077. [Abstract] [Full Text] [PDF]

				R. P. Rother, L. Bell, P. Hillmen, and M. T. Gladwin The Clinical Sequelae of Intravascular Hemolysis and Extracellular Plasma Hemoglobin: A Novel Mechanism of Human Disease JAMA, April 6, 2005; 293(13): 1653 - 1662. [Abstract] [Full Text] [PDF]

				A. Schafer, N. J. Alp, S. Cai, C. A. Lygate, S. Neubauer, M. Eigenthaler, J. Bauersachs, and K. M. Channon Reduced Vascular NO Bioavailability in Diabetes Increases Platelet Activation In Vivo Arterioscler Thromb Vasc Biol, September 1, 2004; 24(9): 1720 - 1726. [Abstract] [Full Text] [PDF]